BioMarin talks down worries on gene therapy data differences

BioMarin Pharmaceutical on Monday laid out its explanation for why Phase 3 results from its closely watched hemophilia A gene therapy appeared to slip from an earlier trial, pointing to differences in steroid use between the two studies.